INmune Bio’s INKmune CaRe PC Trial in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints

August 4, 2025

DENVER, Colo., Aug 04, 2025 (247marketnews.com)- INmune Bio’s (NASDAQ:INMB) Phase I/II clinical trial of INKmune, the CaRe PC trial, in patients with metastatic castration-resistant prostate cancer (mCRPC) has successfully met its primary and secondary endpoints and is now closed to further enrollment.

The CaRe PC trial evaluated the safety, tolerability, and biological activity of INKmune in men with advanced prostate cancer. The study demonstrated that INKmune was well tolerated across all three dose levels, achieving the trial’s primary endpoint of safety.

In addition to its strong safety profile, the trial met its secondary endpoints. Patients with low baseline natural killer (NK) cell activation showed the most pronounced improvements in biomarkers of NK cell activity, identifying a clear target population for subsequent trials.

Dr. Mark Lowdell, INmune Bio’s Chief Scientific Officer, stated, “Excitingly we did see, in some patients, individual tumor lesions either reducing in size or completely disappearing during treatment, so we believe this could be evidence of a direct effect on tumor cell killing.”

INmune Bio plans to advance INKmune into a randomized Phase 2b trial, focused on patients with less advanced disease, to more robustly assess clinical efficacy and therapeutic impact in a more controlled setting.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (INMB)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.